Leqembi® Records Impressive Sales Growth of 18 Billion Yen in Q3 2025

Leqembi® Reports Strong Sales of 18 Billion Yen in Q3 2025

In a remarkable achievement, BioArctic AB’s partner, Eisai, has reported preliminary global revenue figures for their Alzheimer’s treatment, Leqembi®, revealing total sales of 18 billion yen for the third quarter of 2025. This report marks a significant boost from the previous year, reflecting a growing demand and acceptance of the drug used in treating early stages of Alzheimer’s disease.

The royalty income resulting from these sales amounts to approximately SEK 117.2 million for BioArctic, which represents an impressive growth of around 68% compared to the royalties received in the third quarter of 2024. This upturn in revenue is a clear indicator of the increasing efficacy and market presence of Leqembi®, solidifying its position as a leading treatment option for Alzheimer's patients.

The release of this revenue information coincides with the quarterly report of BioArctic and Eisai’s partner, Biogen. This timing underscores the collaborative efforts between these companies and their commitment to advancing Alzheimer’s treatment options. With a full report from BioArctic expected on November 13, 2025, at 8:00 AM CET, stakeholders are eager to gauge the broader impact of these financial results.

Background on Leqembi®

Developed as part of a strategic alliance between BioArctic and Eisai, Leqembi® (lecanemab) is a humanized monoclonal antibody that targets aggregated forms of amyloid-beta (Aβ) - a key contributor to the pathogenesis of Alzheimer’s disease. The drug has gained approval in 51 countries worldwide, including the United States, Japan, China, and throughout the European Union, indicating its global significance in the management of Alzheimer’s. Specifically, it is used to treat patients diagnosed with Mild Cognitive Impairment (MCI) or mild dementia, commonly referred to as early Alzheimer’s.

Furthermore, regulatory reviews are ongoing in nine additional countries, reflecting the drug's potential for broader accessibility and impact. Notably, after an initial 18-month treatment regimen, patients may transition to intravenous maintenance dosing every four weeks, enhancing the medication's convenience and adherence.

In the U.S., Leqembi Iqlik™ offers a recently approved subcutaneous injection option for maintenance dosing, simplifying administration for patients and caregivers alike. The FDA also received a rolling supplemental Biologics License Application (sBLA) for subcutaneous initiation dosing with Leqembi Iqlik in September 2025, indicating the companies' focus on expanding treatment delivery methods.

Clinical Advancements and Collaborations

The ongoing clinical studies involving lecanemab are crucial for understanding its full potential. For instance, Eisai's Phase 3 clinical trial, AHEAD 3-45, specifically targets preclinical Alzheimer’s in patients who show early signs of amyloid accumulation but are clinically normal. This extensive study, fully recruited by October 2024, is a collaborative effort involving the Alzheimer’s Clinical Trial Consortium, Biogen, and major funding from the National Institute on Aging. Meanwhile, since January 2022, the Tau NexGen study focuses on Dominantly Inherited Alzheimer’s Disease, utilizing lecanemab as a cornerstone therapy.

BioArctic and Eisai have maintained a long-term partnership since 2005, focusing on the development and commercialization of Alzheimer’s drugs. The pivotal agreements include the development of the lecanemab antibody, strategically signed in 2007 and followed up with subsequent commercialization agreements. Eisai plays an essential role in the clinical development and regulatory processes while BioArctic retains rights for marketing in the Nordic region, preparing for its commercial launch there.

Overall, BioArctic, headquartered in Sweden, is noted for its innovative biopharmaceutical research, primarily targeting neurodegenerative conditions. Leqembi® stands as a pivotal product that not only represents a breakthrough in Alzheimer's therapy but also showcases the company's commitment to advancing treatments that effectively delay disease progression.

As BioArctic continues to progress, industry observers eagerly await the detailed financial disclosures that may further illuminate the significance of Leqembi® in the fight against Alzheimer's disease. The anticipation surrounding the upcoming findings underscores a collective hope for more effective treatments and improved outcomes for patients worldwide.